ALPHARETTA, GA, Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing.
Clearside Biomedical, Inc., today announced the closing of a $16 million Series B financing. The financing included new investor RusnanoMedInvest (RMI) and existing investors Hatteras Venture Partners, Santen Pharmaceuticals Co. Ltd., Mountain Group Capital and Georgia Research Alliance Venture Fund.
Clearside expects to use proceeds from this financing to fund continued development of Clearside™s proprietary suprachoroidal space (SCS) drug administration and advance its CLS-1001 and CLS-1003 programs into Phase 2 trials by the end of 2014.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye. Clearside™s product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space with Clearside™s proprietary microinjector. Visit www.clearsidebio.com
for more information.
(c) by Massinvestor, Inc. For contact info, please check out our about